ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

amivantamab

Also written as “Amivantamab”, “Amivantamab IV” and “Amivantamab SC”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 2 companies.

Drug pageAmivantamab: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 23, 202016 company-led studies, 13 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only1512 open or runningphase 3since Jul 23, 2020Nov 18, 2015Dec 31, 2026phase 1 · NCT02609776
AstraZeneca11 open or runningphase 2since Mar 24, 2023Mar 24, 2023Oct 1, 2027phase 2 · NCT05801029

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2019Named amivantamabINNProposed as its International Nonproprietary Name in WHO's List 121
  2. Mar 24, 2023First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05801029 · 60 enrolled · Hong Kong, Malaysia, Singapore and more

Ahead

  1. Oct 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05801029

TargetBeta

EGFR →MET →read by rule
“A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
pamvatamigruleBetta Pharmaceuticalsphase 25
TQB2922Sino Biopharmaceuticalphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 11
HLX48Fosun Pharmaphase 11

Studies

The one study AstraZeneca leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05801029Carcinoma, Non-Small-Cell Lung · Hong Kong, Malaysia, Singapore and more2Active, not recruitingOct 1, 202760

How it is read

Names in the registry

  • “Amivantamab”, 15 entries
  • “Amivantamab IV”, 2 entries
  • “Amivantamab SC”, 1 entry
  • “Amivantamab Intravenous”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.